Myriad Genetics Unveils Four-in-One Prenatal Screen
Event summary
- Myriad Genetics launched FirstGene® Multiple Prenatal Screen on July 21, 2026.
- The test combines four prenatal genetic screens into a single blood draw as early as eight weeks gestation.
- Results are delivered in approximately 10 days with >98% analytical sensitivity and >99% specificity.
- FirstGene integrates fetal chromosome screening, fetal single-gene screening, patient carrier screening, and fetal RhD screening.
The big picture
Myriad's FirstGene screen addresses fragmentation in prenatal genetic testing by consolidating multiple screens into one. This aligns with broader trends toward streamlined diagnostic workflows and earlier intervention in pregnancy management. The product expands Myriad's prenatal portfolio, positioning it as a key player in the precision medicine space.
What we're watching
- Adoption Pace
- How quickly obstetricians will integrate FirstGene into standard prenatal care protocols.
- Market Differentiation
- Whether Myriad can sustain competitive advantage against potential entrants with similar multi-screen technologies.
- Reimbursement Dynamics
- The pace at which payers will cover the comprehensive screening, impacting commercial viability.
Related topics